Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder

Jan Volavka, Thomas B. Cooper, Pál Czobor, Morris Meisner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Double-blind haloperidol was administered during two consecutive 3-week periods to 65 patients with acutely exacerbating schizophrenia or schizoaffective disorder. Two plasma levels were targeted: low (2 ng/mL) and moderate (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low). Data from 28 patients were available for the analyses of the second study period. In that period, decrease of plasma levels reduced mild but not severe negative symptoms. Thus, towering of the plasma levels after the first 3 weeks of treatment may improve mild negative symptoms. Conversely, increasing the plasma levels may make mild negative symptoms worse.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalPsychopharmacology Bulletin
Volume32
Issue number1
Publication statusPublished - Jun 18 1996

Keywords

  • haloperidol
  • negative symptoms
  • plasma level
  • schizoaffective disorder
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder'. Together they form a unique fingerprint.

  • Cite this